Table 2: Logistic regression of telomere length on elevated ALT, age 20 and older, and other indicators of suspected nonalcoholic fatty liver disease, NHANES 1999–2002.

Model 1, unadjustedModel 2,
demographic
Model 3, demographic and cell type adjustedModel 4,
demographic, cell type, and abdominal obesity
Model 5, demographic, cell type, and obesity

All races
 All sexes1.87 (1.19–2.94)
(n = 7049)
1.09 (0.651.85)
(n = 6127)
1.14 (0.671.94)
(n = 6115)
1.13 (0.482.65)
(n = 2829)
1.17 (0.522.62)
(n = 3373)
 Male2.95 (1.43–6.09)
(n = 3621)
1.13 (0.492.61)
(n = 3195)
1.12 (0.502.52)
(n = 3191)
0.98 (0.293.24)
(n = 1607)
1.32 (0.424.17)
(n = 1886)
 Female1.25 (0.712.20)
(n = 3428)
0.91 (0.421.98)
(n = 2932)
0.99 (0.442.22)
(n = 2924)
1.087 (0.293.93)
(n = 1222)
0.72 (0.202.57)
(n = 1487)
Other Hispanic
 All sexes5.03 (1.05–24.13)
(n = 312)
4.09 (0.5431.18)
(n = 269)
1.72 (0.1519.44)
(n = 268)
0.74 (0.086.94)
(n = 128)
15.20 (0.27860.28)
(n = 160)
 Male17.00 (1.67–173.24)
(n = 137)
0.52 (0.00834.10)
(n = 126)
0.06 (0.00057.80)
(n = 125)
 Female1.86 (0.2712.75)
(n = 175)
22.51 (0.63807.0)
(n = 143)
37.14 (0.652109.41)
(n = 143)
African-American
 All2.43 (0.866.86)
(n = 1445)
1.86 (0.585.99)
(n = 1190)
1.84 (0.645.18)
(n = 1189)
2.09 (0.656.70)
(n = 479)
3.23 (0.7014.90)
(n = 574)
 Male5.52 (1.38–22.10)
(n = 696)
3.53 (0.7915.73)
(n = 567)
4.98 (1.03–24.13)
(n = 566)
5.56 (0.16192.8)
(n = 291)
5.84 (0.29119.55)
(n = 315)
 Female1.34 (0.325.0)
n = 749
1.46 (0.277.75)
(n = 623)
1.28 (0.354.70)
(n = 623)
2.25 (0.1242.06)
(n = 188)
2.33 (0.1732.77)
(n = 259)
Mexican-American
 All0.65 (0.311.35)
(n = 1201)
0.39 (0.141.09)
(n = 1007)
0.41 (0.151.16)
(n = 1001)
0.37 (0.091.52)
(n = 537)
0.15 (0.03–0.64)
(n = 594)
 Male0.46 (0.191.11)
(n = 537)
0.23 (0.051.04)
(n = 471)
0.22 (0.041.03)
(n = 470)
0.07 (.006–0.79)
(n = 284)
0.012 (0.0006–0.24)
(n = 296)
 Female1.10 (0.196.38)
(n = 664)
1.03 (0.138.36)
n = 536
1.59 (0.2211.54)
(n = 531)
6.00 (0.19188.15)
(n = 253)
0.48 (0.045.38)
(n = 298)
Non-Hispanic White
 All1.93 (1.07–3.49)
(n = 3894)
1.136 (0.622.07)
(n = 3487)
1.20 (0.662.18)
(n = 3483)
0.98 (0.372.55)
(n = 1589)
0.99 (0.332.97)
(n = 1936)
 Male3.01 (1.32–6.91)
n = (2172)
1.22 (0.502.96)
n = 1959
1.31 (0.543.16)
(n = 1958)
0.98 (0.2653.82)
(n = 934)
1.38 (0.365.73)
(n = 1146)
 Female1.29 (0.562.97)
n = (1722)
0.82 (0.322.08)
n = 1528
0.87 (0.352.16)
(n = 1525)
0.44 (0.111.91)
(n = 655)
0.37 (0.071.90)
(n = 790)
Others/mixed race
 All0.14 (0.02–0.92)
(n = 197)
0.00004 (0.000000001–0.14)
(n = 174)
1.00e − 0.06 (2.59e − 11–0.04)
(n = 174)
1.97e − 24 (1.97e − 14–0.18)
(n = 96)
 Male0.01 (0.000033.28)
n = (79)
0.00002 (1.62e − 09–0.18)
n = 72
5.03e − 16 (8.76e – 45 − 2.90 + 13) 
(n = 72)
 Female0.26 (0.041.64)
n = (118)
2.85e − 0.08 (1.61e − 17–50.50) 
(n = 102)
8.46e − 08 (4.25e − 14–0.17)
(n = 102)

Model 1 does not adjust for any covariates. Model 2 adjusts for the following control variables: foreign birthplace, education (less than high school, high school diploma, and more than high school), married and age (as continuous), age squared, and poverty to income ratio. Model 3 adjusts for all the variables in model 2 in addition to cell type composition, blood cells (SI), lymphocytes (%), monocytes (%), platelets (%), basophils (%), eosinophils (%), and neutrophils (%). Model 4 includes all the variables in model 3 and additionally includes abdominal obesity as an outcome (in addition to elevated ALT). Model 5 adjusts for all the variables in model 2 in addition to adding obesity as an outcome (in addition to elevated ALT). Note. ;